Johnson & Johnson (NYSE:JNJ) Shares Bought by Calton & Associates Inc.

Calton & Associates Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 99.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,905 shares of the company's stock after buying an additional 3,440 shares during the period. Calton & Associates Inc.'s holdings in Johnson & Johnson were worth $1,145,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Norges Bank bought a new stake in Johnson & Johnson during the 4th quarter valued at $4,390,037,000. GAMMA Investing LLC raised its stake in shares of Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after buying an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp raised its position in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock worth $1,149,536,000 after purchasing an additional 4,559,147 shares in the last quarter. Finally, Northern Trust Corp grew its position in Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after buying an additional 3,363,235 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 1.6%

Shares of JNJ stock traded up $2.63 during midday trading on Tuesday, reaching $166.99. 4,688,359 shares of the stock were exchanged, compared to its average volume of 8,128,716. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a market cap of $401.79 billion, a PE ratio of 17.87, a price-to-earnings-growth ratio of 2.08 and a beta of 0.41. The company's 50 day moving average is $154.29 and its two-hundred day moving average is $155.12. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter last year, the company posted $2.82 EPS. The company's revenue was up 5.8% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. UBS Group raised their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their target price for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Morgan Stanley lifted their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Eleven research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $172.87.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.